Here we use intravital imaging to demonstrate a reversible transition to a motile state as breast cancer cells spread. Imaging primary tumours revealed heterogeneity in cell morphology and motility. Two distinct modes of motility were observed: collective and single-celled. By monitoring the localization of Smad2 and the activity of a TGFβ-dependent reporter gene during breast cancer cell dissemination, we demonstrate that TGFβ signalling is transiently and locally activated in motile single cells. TGFβ1 switches cells from cohesive to single cell motility through a transcriptional program involving Smad4, EGFR, Nedd9, M-RIP, FARP and RhoC. Blockade of TGFβ signalling prevented cells moving singly in vivo but did not inhibit cells moving collectively.
Breast cancer metastasis starts with cell motility in the primary tumour, leading to either local tissue invasion or entry into lymph or blood vessels 1, 2 . Analysis of fixed clinical material reveals that cancer cells can invade either cohesively or as single cells 3 . Metastases often retain many of the differentiated characteristics of the primary tumour, including cell-cell contacts, but the cell behaviour and signalling that occurs as cells disseminate remains contentious. Epidermal growth factor (EGF) and transforming growth factor β (TGFβ) signalling can promote tumour cell motility [4] [5] [6] . Furthermore, these factors are upregulated in breast cancer and correlate with adverse outcomes [7] [8] [9] . The TGFβ pathway is intriguing because it can promote growth arrest 10 , which seems incompatible with tumour progression. In some cases this paradox is resolved by loss of key mediators of the growth suppressive response to TGFβ in cancer cells [11] [12] [13] .
Alternatively, TGFβ signalling may be active for only limited periods as tumours disseminate and then return to low levels once metastases are established. Similarly, reversible transition of cancer cells of epithelial origin to mesenchymal phenotypes as they metastasize has been suggested 14, 15 . This transition can be driven by TGFβ in experimental systems; however, clinical data is less clear 16 . Signalling pathways may be activated locally within tumours 15 and live imaging studies have shown that tumour cell motility is unevenly distributed within primary tumours 17, 18 . However, heterogeneity in signalling within tumour microenvironments and cell motility have not been studied together.
TGFβ ligands bind to heterotetrameric complexes of receptors with serine-threonine kinase activity leading to an increase in their ability to phosphorylate Smad proteins. When Smad2 and Smad3 are phosphorylated they form complexes with Smad4, which accumulate in the nucleus and regulate transcription 19 . We use live imaging to investigate changes in TGFβ signalling as breast cancer cells become motile in primary tumours and subsequently colonize secondary sites. We demonstrate that TGFβ signalling is transiently and locally activated in disseminating single cells in vivo. Blockade of TGFβ signalling prevents cells moving singly in vivo but permits cells to move cohesively. Single cell motility is essential for blood-borne metastasis, whereas cohesive invasion is capable of lymphatic spread.
RESULTS

Intravital imaging of breast cancer cell dissemination
Rat mammary carcinoma cells (MTLn3E) were engineered to express either actin or a membrane localization sequence fused to GFP to enable imaging of cell morphology before injection into the mammary fat pad. Large areas of MTLn3E tumours contain closely packed cancer cells that retain significant localization of β-catenin to cell junctions ( Fig. 1ai ; Supplementary  Information, Fig. S1a, b ). Most of these cells were non-motile over periods of observation lasting up to 2 h ( Fig. 1aii ; Supplementary Information, Movie 1 and data not shown). Other areas of the tumour had more disorganized cell morphologies and motile cells were observed ( Fig. 1aiii -iv; Supplementary Information, Movie 1, second part); these cells are apparent as adjacent red, green and blue images ( Fig. 1aiv , bii, biii). On average, 5% of cells were motile, but they were not homogeneously distributed. Many tumour areas monitored had no motile cells and other areas had more than 15% of motile cells ( Fig. 1c and data not shown).
A R T I C L E S
Closer inspection revealed that some of the closely packed cells were moving, as shown by non-overlapping red, green and blue images of cell outlines (Fig. 1biii ). In some cases, cells moved in groups several cells wide (Supplementary Information, Movie 2), whereas in other instances, cells were organized into chains only 2-3 cells wide (Supplementary Information, Movie 3). We describe both of these movements as cohesive or collective. Cohesive motile cells accounted for about 20% of all motile cells (Fig. 1d ). Cohesive cell movement was significantly slower than single cell motility (Fig. 1e ). The different morphology and speed of cohesively moving cells suggest that this type of motility is distinct from single cell motility.
Previous studies have shown a correlation between single cell motility and metastasis [20] [21] [22] [23] . In agreement with, this we occasionally observed single motile cells in the process of intravasation ( Supplementary  Information, Fig. S1c, Movie 4) .
Motility is not maintained in lymph node metastases
We next investigated the behaviour of cells that had arrived in the inguinal lymph node. Most cells in lymph nodes were closely packed and non-motile ( Fig. 1fii ; Supplementary Information, Movie 5). Only 2% of cells were motile in larger, more established metastases (Fig. 1g ). In smaller metastases, which presumably contain more recently arrived cells, a slightly higher proportion of motile cells was observed ( Fig. 1g ). Technical limits prevented imaging of the lungs of live mice. These data demonstrate that acquisition of motile behaviour by cancer cells is both a localized and transient event.
Monitoring TGFβ signalling in vivo
TGFβ signalling can increase the invasive potential of cancer cells and promote epithelial to mesenchymal transitions that are implicated in cancer dissemination 14 . Our data predict that the signalling events that promote cancer cell motility are locally and transiently activated. We therefore tested whether activation of TGFβ signalling was associated with motile cancer cells in vivo. We used a TGFβ-dependent reporter (CAGA 12 -luciferase) 24 to confirm that MTLn3E cells can respond to TGFβ ( Fig. 2a ). Furthermore, TGFβ signalling led to a reduction in the growth of MTLn3E cells in soft agar ( Fig. 2b ). Analysis of MTLn3E tumours revealed heterogeneous phosphorylation of Smad3 (indicative of active TGFβ signalling) in vivo, with greatest levels found near the tumour margins and a subset of blood vessels ( Fig. 2c ; Supplementary Information, Fig. S2 ). Analysis of human breast cancer samples and transgene-driven mouse tumours also revealed considerable heterogeneity in TGFβ signalling ( Supplementary Information, Fig. S2d, e ). These data confirm that TGFβ signalling is non-uniformly active in tumours.
Nuclear localization of Smad2 in single motile cells in vivo
To monitor TGFβ signalling with cellular resolution in vivo we adopted two approaches. We engineered MTLn3E cells to express Smad2 fused to GFP, which accumulates in the nucleus in response to TGFβ signalling 25 .
To facilitate visualization of the nucleus, cells were also made to express orange fluorescent protein (OFP) 26 fused to an NLS (Supplementary Information, Fig. S3a, b ). Imaging of tumours expressing GFP-Smad2 and OFP-NLS was performed and GFP-Smad2 localization was correlated with cell behaviour. GFP-Smad2 localization was heterogeneous in vivo. In some cells, Smad2 localization was predominantly cytoplasmic ( Fig. 3a, left) . In other cells, Smad2 was evenly distributed between the nucleus and cytoplasm or predominantly in the nucleus (Fig. 3a , right). Time-lapse analysis revealed that all singly moving cells had Smad2 in the nucleus (Fig. 3bi , c: note colocalization of GFP-Smad2 with OFP-NLS marker in motile cell; Supplementary Information, Movie 6).By contrast, cells moving collectively had Smad2 in the cytoplasm ( Fig. 3bii ; Supplementary Information, Movie 7) . Cytoplasmic localization of Smad2 was also common in non-motile cells ( Fig. 3biii , c; Supplementary Information, Movie 8), although some stationary cells had similar levels of Smad2 in the nucleus as in the cytoplasm. The nuclear accumulation of Smad2 seen in singly moving cells was not found in cells that had disseminated to local lymph nodes or larger lung metastases. However, we occasionally noted nuclear Smad2 in isolated cells in the lungs (Fig. 3d ). These data suggest a transient nuclear accumulation of Smad2 during metastasis.
Activation of a TGFβ reporter in single motile cells in vivo
Nuclear accumulation of Smad2 does not necessarily indicate activation of a transcriptional response. We therefore used a CAGA 12 -CFP reporter to determine which cells had activated a TGFβ transcriptional response ( Supplementary Information, Fig. S3c, d) . Expression of the CAGA 12 -CFP reporter was heterogeneous ( Fig. 4a ). Strikingly, almost all cells moving singly were CFP-positive, whereas collectively moving cells were CFP-negative ( Fig. 4a, b ; Supplementary Information, Movie 9). CAGA 12 -CFP expression was low in lymph node and larger lung metastases, although it was sometimes observed in smaller lung metastases ( Fig. 4a, b ). These observations support the idea of a transient activation of TGFβ signalling in singly moving cells during metastasis. The presence of non-motile cells with nuclear Smad2 and CAGA 12 -CFP expression indicates that TGFβ signalling is not sufficient to drive cancer cell motility.
We confirmed these results using a second breast cancer model. Orthotopic tumours were generated using 410.4 mouse mammary carcinoma cells 27 . Cell motility was observed in only a subset of 410.4 cells (~1%) and most of these cells moved as single cells (data not shown). Importantly, TGFβ signalling was increased in the single cells, as judged by either Smad2 localization or CAGA 12 -CFP expression that was not maintained in lymph nodes (Supplementary Information, TGFβ signalling is implicated in promoting mesenchymal characteristics during cancer invasion. MTLn3E cells express intermediate levels of several mesenchymal markers including Twist, Snail and vimentin. Of these, only the levels of vimentin increased in response to TGFβ treatment ( Supplementary Information, Fig. S3e ). We therefore investigated whether vimentin expression was altered in motile cells in vivo. MTLn3E cells were engineered to contain the vimentin promoter controlling GFP expression and a constitutive promoter driving expression of mRFP-actin ( Supplementary Information, Fig. S3f ). Intravital imaging revealed a heterogeneous pattern of vimentin expression. Similarly to the CAGA 12 reporter, a greater proportion of cells moving singly were positive for vimentin expression ( Fig. 4c ; Supplementary Information, Movie 12), which probably reflects elevated TGFβ signalling. However, in contrast to activation of TGFβ signalling, vimentin expression was also compatible with cohesive movement (Fig. 4c ). We believe that the basal level of vimentin expression in collectively moving cells is not regulated by TGFβ, as GFP-Smad2 and CAGA 12 -CFP cell lines show that TGFβ signalling is very low in these cells.
TGFβ switches cells to single cell motility in vitro
The data presented above show a striking correlation between the mode of migration used and TGFβ signalling in vivo; however, they do not demonstrate that TGFβ causally determines the mode of migration. To test this, we investigated how TGFβ affected the motility of MTLn3E cells. When seeded at low density, MTLn3 cells grow as distinct colonies. Cells within these colonies are constantly in motion but almost never move as single cells away from the colony (Supplementary Information, Movie 13). When cells are cultured in the presence of TGFβ1, they no longer grow as discrete colonies but instead move as single cells (Fig. 5a, b ). This response could be quantified by calculating the average area occupied by a cell before a neighbouring cell is present. The kinetics of the switch to single cell motility were slow ( Fig. 5a ). Prolonged exposure to TGFβ1 promoted an increase in actin stress fibres and loss of β-catenin localization from cell-cell contacts (Fig. 5b ). Consistent with this observation, we found that tumour areas with high pSmad3 levels had lost β-catenin localization at cell-cell contacts ( Supplementary Information, Fig. S5a ). 410.4 cells underwent similar changes in motility and morphology following TGFβ1 treatment ( Supplementary Information, Fig. S6a ). In contrast to TGFβ, EGF did not promote cell scattering but increased the speed at which cells moved in cohesive groups ( Supplementary Information, Fig. S6b , c). The slow kinetics of the response to TGFβ suggests that the switch to single cell motility may be driven by transcriptional responses mediated by Smad transcription factors. In both MTLn3E and 410.4 cells, transfection of siRNA targeting Smad4 markedly reduced cell scattering in response to TGFβ, whereas depletion of Smad3 led to a more modest reduction in scattering ( Fig. 5c -e; Supplementary  Information, Fig. S6b ). Having established a key role for TGFβ-mediated transcription, we performed microarray analysis to identify TGFβ target genes in MTLn3E cells. A large number of genes were regulated by TGFβ signalling, including many well established targets (CTGF and PAI-1). Several poorly characterized TGFβ-regulated genes were also identified (Supplementary Information, Table S1 with qRT-PCR confirmation and Smad4-dependence shown in Supplementary Information, Fig. S7 ). Many of these genes could potentially be implicated in the switch away from cohesive cell motility. EGFR, AP-1 family members (c-Jun and JunB), various proteins involved in Rho signalling (RhoC, MPRIP, a Rho-interacting regulator of myosin phosphatase activity, Farp1, a FERM domain-containing Rho exchange factor, Nedd9, an atypical Rac activator and RhoQ/TC10), and a range of molecules implicated in cell-cell adhesion, could all affect the mode of cell motility (Supplementary Information, Table S1 ). We tested whether these genes were required for the switch from cohesive to single cell motility. Depletion of MPRIP, Farp1, Nedd9, c-Jun, EGFR and CTGF all reduced TGFβ-induced cell scattering ( Fig. 6a ), although none completely abrogated the response. Depletion of RhoC alone had little effect, but combined depletion of RhoC and its close homologue RhoA significantly reduced cell scattering. Similar results were obtained in 410.4 cells ( Supplementary Information, Fig. S6c ). We also used multiple siRNA sequences to confirm the effect of one of the less well studied target genes, MPRIP ( Supplementary Information, Fig. S6e , f). We further demonstrated the importance of Rho-mediated regulation of contractility, EGFR signalling and JNK/c-Jun signalling using the pharmacological inhibitors Y27632 (targets Rho-ROCK signalling), AG1478 (targets EGFR) and SP600125 (targets JNK signalling) ( Fig. 6 ; Supplementary  Information, Fig. S6d ).
To understand how TGFβ target genes promote single cell motility, we investigated their role in adherens junction organization, cell motility and F-actin organization. Depletion of RhoA&C together, Farp1, MPRIP and c-jun reduced adherens junction disruption following TGFβ treatment, whereas EGFR, Nedd9 and CTGF depletion had little effect ( Fig. 6c ). Although some TGFβ targets were not required for adherens junction disassembly, they may be needed for other aspects of single cell motility. We tested this by culturing cells under conditions that favour single 'amoeboid-type' cell motility 28 and analysing their movement and morphology (Supplementary Information, Movie 14). EGFR, Nedd9 and c-Jun were all required for efficient amoeboid motility and this corresponded with defects in the formation of F-actin rich protrusions at the front of the cell (Fig. 6d , e, protrusions marked with arrows). The effects of targeting Rho signalling through depletion of RhoA&C, MPRIP or Farp1 were less pronounced, although in all cases elongated cells with tail retraction defects were observed. Together these data indicate that TGFβ promotes single cell motility by regulating a transcriptional programme with different genes playing distinct roles in the switch.
TGFβ signalling switches cells from cohesive to single cell movement in vivo
We further tested the role of TGFβ in cohesive and single cell motility by blocking signalling in a cell autonomous manner. MTLn3E cells were generated that expressed a 'dominant-negative' TGFβ type-II receptor fused to GFP (TGFβRDN-GFP; Supplementary Information, Fig. S8a -c). The behaviour of these cell lines was compared with control cell lines in vivo. Figure 7a shows intravital imaging of a 'mosiac' tumour containing CFP-expressing control cells and TGFβRDN-GFP expressing cells. Although numerous control cells were observed moving as single cells, none of the TGFβRDN-GFP expressing cells were motile (Supplementary Information, Movie 15). Analysis of numerous tumours revealed that cells expressing TGFβRDN-GFP could still move cohesively (shown by imperfect overlay of red, green and blue images in Fig. 7b and Supplementary Information, Movie 16). Indeed, this type of motility was observed more frequently ( Fig. 7c ). Comparable numbers of motile control and TGFβRDN-GFP cells were observed, but there was a striking switch in the type of motility.
To test whether TGFβ-driven transcription is needed for this switch, we generated clones stably depleted of Smad4 ( Supplementary  Information, Fig. S8d-f ). Intravital imaging confirmed that Smad4 is required for single cell motility ( Fig. 7d ). Our in vitro analysis suggests that TGFβ-driven transcription of various regulators of Rho/ ROCK signalling is required for the switch to single cell movement. New analysis of ROCK inhibition in vivo 28 revealed a greater requirement for Rho/ROCK signalling for single cell movement as opposed to collective movement ( Supplementary Information, Fig. S9 ). These data support a role for TGFβ-dependent upregulation of this pathway in single cell motility. In a reciprocal approach we investigated the effect of activating TGFβ signalling. Cells stably overexpressing TGFβ1 were generated (characterized in Supplementary Information, Fig. S8g , h) and their behaviour in vivo investigated. These cells showed greatly increased single cell motility in vivo, although not all TGFβ1-expressing cells were motile ( Fig. 7e ; Supplementary Information, Movie 17). These data demonstrate that TGFβ signalling is necessary for single cell motility in vivo and that its ectopic expression promotes single cell motility.
Mode of cell motility determines haematogenous versus lymphatic spread
The results presented so far have focused on cell motility but have not addressed how this relates to metastasis. To investigate this, we generated mixed tumours containing control and experimentally manipulated cells, and measured the relative efficiency of the cells to spread to the inguinal and axillary lymph nodes, enter the blood and form lung metastases. Both TGFβRDN-expressing cells and Smad4 shRNA cells showed reduced entry into the blood and lung colonization ( Fig. 8a, b ). Interestingly, their spread to lymph nodes was similar to control cells, suggesting that collective invasion may be used for lymphatic spread. To see whether this was true, we performed extensive imaging of tumour cells near lymphatic vessels. Figure 8e shows a chain of MTLn3E cells extending into a lymphatic vessel. Time-lapse analysis of this region shows that they are moving into the vessel (Supplementary Information, Movie 18). We also observed numerous examples of groups of cancer cells within lymphatic vessels, including TGFβRDN cells (Fig. 8e ). These data demonstrate that collective invasion can mediate lymphatic dissemination.
TGFβ1-overexpressing cells had an increased ability to enter the blood but this was not reflected in the overall numbers of lung metastases (Fig. 8c) . The reduced lung metastases may reflect the growth inhibitory effects of TGFβ observed when measuring growth in soft agar (Fig. 2) . To test this we directly measured lung colonization following tail vein injection of a 1:1 mixture of control and constitutively overexpressing TGFβ1 cells. Two weeks after injection TGFβ1 cells were significantly under-represented in lung metastases (Fig. 8d ). This was not caused by a defect in the initial stages of lung colonization because 24 h after injection these cells were overrepresented in the lungs. Cells pulsed with TGFβ1 ligand to induce a transient burst of signalling are favoured at both the early and late stages 
Cell scattering index/a.u. of lung colonization ( Fig. 8d and refs 29, 30 ). These data demonstrate that prolonged TGFβ signalling does not favour lung colonization and that the ability to downregulate signalling is crucial for the growth of lung metastases. Thus optimal lung metastasis depends on both the ability to initially turn TGFβ signalling on and subsequently to turn it off.
DISCUSSION
Many studies have proposed localized and transient changes in signalling as cells metastasize. Tumour imaging has shown that only a small proportion of cancer cells are motile even around the margins of metastatic breast cancer models 17 . This observation suggests that the signalling pathways that promote cancer cell motility may be heterogeneously active in tumours. We used intravital imaging of breast cancer cells engineered to express fluorescent reporters of TGFβ signalling to demonstrate localized and transient activation of signalling. Two distinct modes of motility, collective and single, were observed in vivo. These modes differ in their speed and presence of cell-cell contacts, which probably reflects the differing patterns of invasion observed by pathologists 3 . TGFβ signalling is active in singly moving cells but not in those moving cohesively; furthermore blockade of TGFβ signalling switches cells to cohesive motility. However, TGFβ signalling is not sufficient to drive cancer cell motility. We propose that other factors besides TGFβ determine whether cancer cells become motile. If TGFβ is also active, then single cell dissemination will occur, whereas if it is not active then cohesive invasion occurs ( Supplementary Information, Fig. S10 ). EGF could be one such additional factor that may be heterogeneously distributed in tumours 23, 31 .
The switch to single cell motility requires regulation of a transcriptional program by TGFβ and Smad4. Different target genes are involved in modulating different aspects of cell behaviour required for single cell motility. Increased EGFR levels could promote sensing of chemotactic cues, whereas Nedd9 promotes actin polymerization. RhoC, MPRIP and Farp1 combine to increase acto-myosin contractility, which is important for destabilising cell-cell junctions and tail retraction in singly-moving cells.
Transient activation of TGFβ signalling could also explain why the growth-suppressing effects of TGFβ do not lead to slow tumour growth. TGFβ signalling is low in the bulk of primary tumours and metastases, thereby allowing growth, and is active only as cells disseminate. Strikingly, although forced and prolonged activation of TGFβ signalling promoted single cell motility in vivo, it failed to promote lung metastasis. This was caused by failure of cells with high levels of TGFβ signalling to proliferate in the lungs. These observations highlight the importance of being able to downregulate TGFβ signalling at certain stages of the metastatic process. It is tempting to speculate that singly moving cells become more mesenchymal; however the available data provides only modest support for this hypothesis. Expression of Snail, Slug and Twist is not altered by TGFβ treatment (data not shown). Although vimentin expression is modulated by TGFβ signalling, it was observed in a significant proportion of non-motile cells and collectively-moving cells. Thus, changes in vimentin expression may merely indicate increased TGFβ signalling, and not that expression of mesenchymal markers drives the switch to single cell motility.
A feature of this work is heterogeneous activity of TGFβ signalling in tumours. Immunohistochemical analysis suggests that TGFβ signalling is active in about 10% of cells throughout the tumour. Even in the tumour margins that we analysed by live imaging, the proportion of cells with active signalling is only 30-50% (Figs 3, 4 ). Analysis of human breast cancer samples shows considerable heterogeneity in TGFβ signalling, suggesting that observations from our model systems are highly relevant ( Supplementary Information, Fig. S2 ), which raises the questions as to the source of this variation. We observed in experimental tumours that TGFβ signalling is greatest around tumour margins and blood vessels. These areas also have the greatest numbers of host cells. Species-specific RT-PCR for TGFβ ligands reveals that they are expressed by both murine host cells and rat MTLn3E cells (data not shown). We believe that much of the heterogeneity results from uneven distribution of TGFβ-producing non-tumour cells or possibly leaky vasculature. The reduction in TGFβ signalling at secondary sites may simply be caused by the cells being displaced from the TGFβ-rich microenvironments that activated signalling in the primary tumour.
TGFβRDN cells Control cells Matrix
Previous work had suggested rather stable changes in TGFβ signalling during cancer progression, often associated with a loss of anti-proliferative responses 12 . This was thought to occur either globally or for metastasis to specific sites 32, 33 . We provide a new framework for changes in TGFβ signalling in metastatic cancer. Loss of anti-proliferative responses is not necessary because TGFβ signalling is low in most cancer cells in primary locations and metastases. TGFβ signalling is transiently active only in a small population of cells; activation of TGFβ signalling in these cells drives expression of a range of genes that promote single cell motility. Cells that do not upregulate TGFβ signalling are still observed moving collectively and can enter lymphatic vessels. Therefore, the mode of cancer cell motility influences whether cancers metastasize via lymphatic or haematogenous routes. The activation of TGFβ signalling that promotes entry into the blood needs to be reduced for efficient growth of metastases in the lungs. Thus, reversible changes in TGFβ signalling are necessary for blood-borne metastasis of breast cancer models.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturecellbiology/ Note: Supplementary Information is available on the Nature Cell Biology website.
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M E T H O D S METHODS
Plasmids.
To generate the CAGA 12 ::ECFP, the luciferase gene from CAGA 12 ::luc 24 was replaced with ECFP (Clontech). Expression of the GFP-Smad2 fusion protein was driven by a fusion of the EF-1α promoter and β-globin 5´UTR; the GFP-Smad2 fusion is described elsewhere 34 . To generate dominantnegative TGFβ receptor II-GFP fusion, the EGFP coding sequence was cloned at the carboxy-terminal of amino acid 191 of human dominant-negative TGFβ receptor II. The myr-EGFP and myr-Cherry constructs were a gift from Frank Gertler (MIT, Boston, USA). mRFP-actin was a gift from Michael Way (Cancer Research UK, London). Vimentin promoter-GFP was a gift from Christine Gilles 35 . The Smad4 shRNA vector was made by cloning GCAGGTGGCTGGTCGGAAAttcaagagaTTTCCGACCAGCCACCTGCttttt into pRetroSuper (equivalent to Smad4 siRNA no. 3). TGFβ1 IRES-GFP was made by cloning mouse TGFβ1 into pI-EGFP2.
Cell lines. MTLn3E cells were grown in αMEM (GIBCO) containing 5% fetal calf serum (FCS). GFP-Smad2 OFP-NLS (hereafter called Orange-NLS) cells lines were generated by co-transfection of the GFP-Smad2 plasmid together with pBabe-Puro, followed by selection with puromycin (2.5 mg ml -1 ). Following fluorescent activated cell sorting (FACS), a polyclonal cell line was obtained expressing GFP-Smad2. These cells were infected with lentivirus containing a CMV Orange-NLS cassette. Double-positive cells were sorted by FACS to produce one polyclonal cell line and different monoclonal cell lines. Stable MTLn3E myr-cherry CAGA 12 ::ECFP cell lines were generated by infection of MTLn3E with lentivirus containing a CMV myr-Cherry cassette. After FACS sorting a polyclonal cell line, these cells were further transfected with the CAGA 12 ::ECFP construct in combination with pBabe-Puro. Following selection with puromycin, cells were induced with TGFβ1 for 6 h and cells positive for CFP and mCherry were FACS-sorted as single cells. Stable TGFβRDN MTLn3E cell lines were selected following plasmid transfection and single cell clones were chosen for further analysis. Stable Smad4 shRNA MTLn3E cell lines were selected following retroviral infection and single cell clones were chosen for further analysis. A polyclonal pool of cells expressing TGFβ1 IRES-GFP were selected using puromycin followed by FACS sorting. Tumour imaging. Female nude mice (5-6 weeks old) were injected in the mammary fat under the fourth nipple with 10 6 cells for each cell line. When tumours reached 5-7 mm diameter (usually after 21-26 days), mice were anaesthetised and tumours exposed as described previously 22 . The Chameleon Coherent Ti-Sapphire laser was tuned to 870 for EGFP excitation and to 850 for ECFP excitation. For simultaneous imaging of EGFP or ECFP with either Orange, Cherry or mRFP, a single photon 543 laser was fired simultaneously to the Ti-Sapphire laser. Collagen was visualized through second harmonic generation. Typically, four different areas were imaged for 20-30 min in each tumour. Cell speeds were determined for motile cells that remained visible in the same confocal section for several minutes using LSM image examiner. Cells that moved between confocal sections were not analysed for speed. Where appropriate, drift in the x-y plane was corrected using Imaris software before analysis. Lymphatic vessels were visualized by injection of 10-20 μl of high molecular weight TRITC-dextran into the tumour.
Smad2 localization analysis.
To analyse intravital movies of GFP-Smad2 localization, we categorized cells into having either cytoplasmic, nuclear and cytoplasmic, or nuclear Smad2. The nucleus was defined by Orange-NLS expression and we then measured the GFP-Smad2 pixel intensity in the nucleus and the cytoplasm. If these values were within 33%, then we categorized the cell as having both nuclear and cytoplasmic Smad2, otherwise it was categorized as having either nuclear or cytoplasmic Smad2. CAGA 12 -CFP and vimentin promoter-GFP analysis. Microscope settings were kept constant for each individual tumour analysed, meaning that all images from a mouse are internally consistent. Slight differences between tumour position and the amount of surrounding tissue meant that it was not always possible to use identical settings between mice; nonetheless we tried to ensure that average pixel intensities were similar for all mice. Cells were simply divided into CFP or GFP negative (no signal above background noise) or positive (signal above background noise). We also tried to subdivide positive cells, depending on their amount of signal, but this did not provide any further statistically significant insights (data not shown).
Analysis of cells in lymph nodes, blood and lungs.
The numbers of disseminating cells were determined after killing the mice. Inguinal and axillary lymph nodes were dissected and examined whole with a fluorescence microscope to determine the numbers of mCherry or mRFP and GFP-positive cells. The lungs and heart were dissected together and the blood drained from the heart into a cell culture dish. Some PBS was added and the cells allowed to settle before the entire dish was scanned for mCherry or mRFP and GFP positive cells. The lungs were examined in a similar manner to the lymph nodes. The values shown in Fig. 8b and c are the number of experimentally manipulated cells observed (green) divided by the number of control cells (red) in the lymph node, blood or lungs normalised to the ratio of experimentally manipulated cells to control cells observed in the primary tumour.
Luciferase assays. MTLn3E cells (10 5 ) were transfected, using Fugene 6 (Roche), with of CAGA 12 ::luc (2.0 μg) in combination with EF-LacZ (1 μg). Six hours after transfection, cells were treated for 18 h with either TGFβ1 (2 ng ml -1 ), SB431542 (10 μm), DMSO (1:1000) or combinations thereof. Using the luciferase assay kit (Promega), luminescence was assayed in Wallac 1420 plate reader. For each sample, luciferase activity was divided by β-galactosidase activity. Values are expressed as fold activation relative to the untreated control cells.
Soft agar assay. Cells were treated for 18 h with either DMSO, TGFβ1 (2 ng ml -1 ) +DMSO or SB431542 (10 μM) before washing with PBS and preparation for the soft agar assay. Base agar was prepared at 42°C by mixing 2× medium (αMEM + 5% FCS) with 1.2% agarose dissolved in water, adding.5 ml to 6 well plate and allowing the plates to set for >30min at room temperature. Top agar was prepared by mixing 2× medium (αMEM + 5% FCS) with 0.75% agarose gel dissolved in water and adding 1.5 ml to 5,000 pelleted cells. The mixture was then overlaid on the base agar. Plates are allowed to set for 30 min at room temperature, then overlaid with αMEM + 5% FCS, which was changed twice weekly. At day 21-24, plates were fixed for 10 min in ice cold 10% methanol and stained with Giemsa stain. Excess stain was removed by washing with water and visible colonies were then counted.
Western blotting. Whole-cell extract were prepared using D0.4 buffer (20 mM Hepes pH 7.5, 10% glycerol, 0.4 M NaCl, 0.4% Triton X-100, 10 mM EGTA, 5 mM EDTA 1 M dithiothreitol, 1× protease inhibitors (Roche), 10 mg ml -1 aprotonin). For cytoplasmic/nuclear fractionation, cells were treated as described previously 36 . Western blotting was performed using standard procedures. The following primary antibodies were used in this work: Smad2/3 (1:500; BD, no. 610843), pSmad2 (1:800; Cell Signaling, no. 3101), Smad3 (Zymed, no. 511500), Smad 4 (1:1,000; Santa Cruz, sc-7966), β-tubulin (Sigma), PARP (1:1,000; Roche, no. 1183528001), Grb2 (1:1,000), vimentin (Santa Cruz, sc-6260), anti-GFP (Roche, no. 11814460001).
Immunofluorescence. Cells were fixed using 4% paraformaldehyde in PBS then permeabilized with 0.25% Triton X100. After blocking with 5% BSA, primary antibodies against β-catenin y (Santa Cruz sc-7963) or pS63-c-Jun (Santa Cruz sc-822) were diluted in 1% BSA in PBS and incubated with sample overnight at 4°C. Secondary antibodies and/or phalloidin were diluted in 1% BSA in PBS and incubated with sample for 1 h at room temperature.
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Tumour staining. Frozen tumour samples, either MTLn3E or human breast carcinoma, were fixed using 4% paraformaldehyde in PBS following by 0.2%Triton X100 in PBS and blocked with 5%BSA in PBS. The following antibodies were used: pSmad3 423/425 (Cell Signaling, no. 9514), pSmad3 423/425 (Epitomics, no. 1880), Smad2/3 (BD, no. 610843), β-catenin (Santa Cruz, no. 7963), CD31 (BD Pharmingen, no. 553370) and TRITC-phalloidin and DAPI were used to visualize F-actin and DAPI, respectively. Primary antibodies were used at a 1:100 dilution.
Inhibitors and recombinant proteins. Recombinant TGFβ1 (Peprotech) was dissolved in 4 mM HCl + 1 mg ml -1 BSA at a stock concentration of 1 μg ml -1 . The following inhibitors were used at working concentrations of 10 μM: SB431542 (ALK4,5,7; Tocris), Y27632 (ROCK1 and 2; Tocris), AG1478 (EGFR; Sigma), SP600125 (JNK; Calbiochem), UO126 (MEK).
Scattering assay. Cells were plated as single cells at low density, so that each single cell could produce a small cluster. Cells were plated and 18-24 h later were treated for a further 18-24h with TGFβ alone or in combination with inhibitors. For MTLn3E cells the extent of scattering was determined by measuring the area underlying a colony divided by the number of cells within that colony (scattering index). For 410.4 cells, the number of single cells per ×10 microscope field was counted in four fields for each condition. For time-lapse imaging of these assays, cells were treated for 36-40 h before imaging.
Lung colonization assay. TGFβ1-IRES-GFP or control MTLn3E cells (5 × 10 5 , labelled with mCherry) were mixed in 100 μl PBS and injected intravenously into mice. For the 'pulse' experiment GFP MTLn3E cells were treated with TGFβ (2 ng ml -1 ) for 18 h before injection. Mice were killed after either 48 h or two weeks, lungs were removed and micro-metastases visualized using a fluorescence microscope and the ratio of red to green cells determined.
Microarray procedures and analysis. Total RNA (5 mg) was labelled according to Affimetrix genechip microarray protocol. The labelled RNA was hybridized to rat genome 230 2.0 arrays. Samples for three independent repeats of each experimental condition were sent for analysis. Five conditions were assessed, namely DMSO 1:1000 for 18 h, SB431542 (10 μM) for 18 h, TGF B1 (2 ng ml -1 ) + DMSO for 18 h, TGFβ1 (2 ng ml -1 ) + DMSO for 2 h, TGF-β1 (100 pg ml -1 ) for 18 h. Expression levels of genes in TGFβ1 or SB431542-treated cells were compared with that of uninduced cells. Fold changes greater than 2-fold with P <0.000001 were deemed TGFβ1-regulated. Expression analysis was carried out at the Bioinformatics 
Cell motility
Tail retraction Box 1 The switch to single cell motility requires regulation of a transcriptional program by TGF and Smad4. We have identified several TGF target genes that play a role in this transition and furthermore, maximal transcription of some of these genes also requires Smad4 (Supplementary Figure 7C) . At least three genes involved in Rho signalling, RhoC, MPRIP and Farp1, are involved in the initial dissolution of adherens junctions and in retracting the tail of singly moving cells. Both of these phenotypes could be accounted by defective acto-myosin force generation. Inhibiting Rho/ROCK signalling in vivo contractility using Y27632 dramatically reduced the number of singly moving cells while cells moving cohesively were less affected. EGFR and Nedd9 are required for the formation of F-actin rich protrusions that drive single cell motility. Previous data has shown that increased EGFR expression increases cell motility in primary tumours and intravasation leading to increased lung metastasis. The function of JNK/c-jun signalling is also important for the switch to single cell motility even though TGF only has a modest effect on the activity of this pathway ( Supplementary Figure 7) . It is possible that JNK/c-jun signalling and TGF signalling co-operate to regulate genes required for single cell motility. Indeed, we found that MPRIP and Farp1 mRNA levels were dependent on c-jun (data not shown). Together these data demonstrate that TGF controls a broad transcriptional program that switch cells to individual modes of movement. 
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